Page last updated: 2024-11-04

dichlorphenamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dichlorphenamide is a carbonic anhydrase inhibitor. It is used to treat glaucoma, a condition that damages the optic nerve, which connects the eye to the brain. This damage is often caused by high pressure inside the eye. Dichlorphenamide lowers eye pressure by reducing the production of aqueous humor, the fluid that fills the space between the cornea and the lens. Dichlorphenamide is available as a tablet and as an eye drop. Side effects of dichlorphenamide can include nausea, vomiting, and diarrhea. It has been studied for its potential use in treating other conditions, such as epilepsy and altitude sickness.'

Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3038
CHEMBL ID17
CHEBI ID101085
SCHEMBL ID112376
MeSH IDM0006280

Synonyms (134)

Synonym
MLS002154010
smr001233338
BRD-K71499074-001-03-8
BSPBIO_000677
diclofenamid
glajust
m-benzenedisulfonamide, 4,5-dichloro-
einecs 204-440-6
cb 8000
dichlorphenamid
daranide
oratrol
barastonin
diclofenamidum [inn-latin]
diclofenamida [inn-spanish]
brn 2703329
glauconide
antidrasi
glaumid
hsdb 3267
glaucol
glafco
PRESTWICK_1071
1,3-benzenedisulfonamide, 4,5-dichloro-
NCGC00016371-01
cas-120-97-8
PRESTWICK3_000809
PRESTWICK2_000809
BPBIO1_000745
C07459
diclofenamide
120-97-8
dichlorphenamide
i7a ,
4,5-dichlorobenzene-1,3-disulfonamide
1,3-disulfamoyl-4,5-dichlorobenzene
dichlorophenamide (dcp)
4,5-dichloro-1,3-disulfamoylbenzene
dichlofenamide
chembl17 ,
4,5-dichloro-1,3-benzenedisulfonamide
3,4-dichloro-5-sulfamylbenzenesulfonamide
dichlorophenamide
DB01144
1,3-disulfamyl-4,5-dichlorobenzene
4,5-dichloro-m-benzenedisulfonamide
4,5-dichloro-benzene-1,3-disulfonic acid diamide
bdbm10883
sulfonamide 4
dichlorophenamide, dcp
D00518
keveyis (tn)
daranide (tn)
dichlorphenamide (usp)
diclofenamide (jan/inn)
SPBIO_002598
PRESTWICK1_000809
PRESTWICK0_000809
NCGC00016371-02
2POU
diclofenamida
CHEBI:101085 ,
diclofenamidum
HMS1570B19
A21072
HMS2097B19
tox21_110401
dtxcid402922
dtxsid1022922 ,
HMS2236I07
dasanide
dichlorphenamide [usp]
unii-vvj6673mhy
diclofenamide [inn]
vvj6673mhy ,
keveyis
FT-0648264
NCGC00016371-05
diclofenamide [who-dd]
dichlorphenamide [mi]
dichlorphenamide [hsdb]
dichlorphenamide [orange book]
diclofenamide [mart.]
dichlorphenamide [usp impurity]
dichlorphenamide [usp-rs]
dichlorphenamide [usp monograph]
diclofenamide [jan]
AKOS015899860
S2177
gtpl6807
HMS3373G04
CCG-220809
HY-B0397
SCHEMBL112376
NCGC00016371-04
W-108466
4,5-dichloro-m-benzendisulfonamide
4,5-dichloro-1,3-benzenedisulfonamide #
AC-25007
EX-A1311
sr-01000841825
SR-01000841825-2
dichlorphenamide, united states pharmacopeia (usp) reference standard
HMS3655H06
AS-63955
HMS3714B19
NCGC00016371-06
4,5-dicholorobenzene-1,3-disulfonamide
SW197138-3
BCP22591
diclofenamide; dichlofenamide; daranide; 4,5-dichlorobenzene-1,3-disulfonamide
Q3706987
dichlorphenamide (diclofenamide)
mfcd00148948
AMY7513
HMS3745K19
NCGC00016371-08
EN300-761460
4,5-dichlorobenzene1,3-disulfonamide
diclorfenammide
diclorfenamida
cb8000
diclofenamide (mart.)
dichlorphenamide (usp impurity)
dichlorphenamide (usp-rs)
dichlorphenamide (usp monograph)
diclofenamidum (inn-latin)
diclofenamida (inn-spanish)
dichlofenamid
s01ec02
daramide
Z2037279821
F90397
dichlorphenamide, secondary standard

Research Excerpts

Overview

Oral dichlorphenamide (Keveyis™) is a carbonic anhydrase inhibitor. It is approved in the USA for the treatment of primary hyperkalaemic and hypokalaemic periodic paralyses.

ExcerptReferenceRelevance
"Oral dichlorphenamide (Keveyis™) is a carbonic anhydrase inhibitor that is approved in the USA for the treatment of primary hyperkalaemic and hypokalaemic periodic paralyses and related variants. "( Dichlorphenamide: A Review in Primary Periodic Paralyses.
Greig, SL, 2016
)
2.39

Toxicity

Dichlorphenamide was comparably effective and tolerated among a small number of adolescents as well as adults. The most common adverse event with dichlor phenamide in adolescents was skin rash.

ExcerptReferenceRelevance
" The most common adverse event with dichlorphenamide in adolescents was skin rash (two of six [33%])."( Efficacy and Safety of Dichlorphenamide for Primary Periodic Paralysis in Adolescents Compared With Adults.
Ciafaloni, E; Cohen, F; Griggs, R, 2019
)
1.1
"Dichlorphenamide was comparably effective and tolerated among a small number of adolescents as well as adults, although types of adverse events differed between groups."( Efficacy and Safety of Dichlorphenamide for Primary Periodic Paralysis in Adolescents Compared With Adults.
Ciafaloni, E; Cohen, F; Griggs, R, 2019
)
2.27
" Common adverse events (AEs) were paresthesia and cognition-related events, which typically first occurred within 1 month of blinded treatment initiation and in rare cases led to treatment discontinuation."( Long-term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis.
Ciafaloni, E; Cohen, F; Griggs, RC; Hanna, MG; Johnson, NE; Sansone, VA; Shieh, PB; Statland, JM, 2021
)
0.9
"One-year open-label DCP treatment after a 9-week randomized, controlled study confirmed long-term DCP remains safe and effective for chronic use."( Long-term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis.
Ciafaloni, E; Cohen, F; Griggs, RC; Hanna, MG; Johnson, NE; Sansone, VA; Shieh, PB; Statland, JM, 2021
)
0.9

Pharmacokinetics

ExcerptReferenceRelevance
"5-3 hours, and mean half-life from 32-68 hours."( Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers.
Cohen, F, 2019
)
0.73

Bioavailability

ExcerptReferenceRelevance
" Furthermore, the bioavailability of these derivatives in rabbits is comparable to that of acetazolamide, being in the range of 85-90%, showing them as promising candidates for systemically acting CA inhibitors."( Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
Scozzafava, A; Supuran, CT, 2002
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Mean area under the concentration-time curve from time 0 to tau (length of the dosing interval estimated using the trapezoidal method) and maximum observed plasma concentration increased dose-proportionally after multiple doses."( Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers.
Cohen, F, 2019
)
0.73
" Dichlorphenamide total daily dosing among adolescents was 50 mg (n = 1) or 100 mg (n = 5), and in adults was 105."( Efficacy and Safety of Dichlorphenamide for Primary Periodic Paralysis in Adolescents Compared With Adults.
Ciafaloni, E; Cohen, F; Griggs, R, 2019
)
1.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 4.2.1.1 (carbonic anhydrase) inhibitorAn EC 4.2.1.* (hydro-lyases) inhibitor that interferes with the action of carbonic anhydrase (EC 4.2.1.1). Such compounds reduce the secretion of H(+) ions by the proximal kidney tubule.
antiglaucoma drugAny drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
ophthalmology drugAny compound used for the treatment of eye conditions or eye diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (69)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.12200.003245.467312,589.2998AID2517
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
AR proteinHomo sapiens (human)Potency9.34160.000221.22318,912.5098AID743035; AID743063
EWS/FLI fusion proteinHomo sapiens (human)Potency0.46860.001310.157742.8575AID1259256
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.04140.000229.305416,493.5996AID743080
GVesicular stomatitis virusPotency7.56370.01238.964839.8107AID1645842
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency3.62250.001019.414170.9645AID743094
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.63100.00636.904339.8107AID883
gemininHomo sapiens (human)Potency0.79430.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency17.35980.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency0.35480.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency7.56370.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency7.56370.01238.964839.8107AID1645842
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency0.63100.00638.235039.8107AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency8.91250.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency7.56370.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency7.56370.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki0.03800.03800.05870.0750AID977610
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki0.03800.03800.05870.0750AID977610
Chain A, Carbonic anhydrase 2Homo sapiens (human)Ki0.03800.03800.05870.0750AID977610
Carbonic anhydrase Astrosclera willeyanaKi0.06200.03201.51729.6000AID644379
Carbonic anhydrase Sulfurihydrogenibium sp. YO3AOP1Ki0.00850.00450.16240.8760AID1268964
Carbonic anhydrase Stylophora pistillataKi0.43100.00000.686710.0000AID436565; AID552130
Carbonic anhydraseStylophora pistillataKi0.07900.00000.50715.7100AID552131
Carbonic anhydraseHelicobacter pylori 26695Ki0.37050.02000.54864.3600AID261581; AID263638
Carbonic anhydrase 12Homo sapiens (human)Ki16.68390.00021.10439.9000AID1062684; AID1154448; AID1204091; AID1347714; AID1379906; AID1796980; AID1798598; AID1799734; AID1803440; AID238316; AID238467; AID239126; AID239284; AID258733; AID271040; AID272527; AID293193; AID311032; AID327767; AID486935; AID496922; AID512004; AID598015; AID603451; AID610538; AID614108; AID620688; AID697241
Prolyl endopeptidaseRattus norvegicus (Norway rat)Ki0.63000.00000.10840.6300AID578223
Bile salt export pumpHomo sapiens (human)IC50 (µMol)919.10000.11007.190310.0000AID1449628
Glycogen phosphorylase, muscle formOryctolagus cuniculus (rabbit)Ki0.34500.02504.89039.0000AID614109
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)1.20000.00582.14107.9000AID50344; AID50345
Carbonic anhydrase 1Homo sapiens (human)Ki7.31010.00001.372610.0000AID1062687; AID1140817; AID1142833; AID1154445; AID1188134; AID1190063; AID1194024; AID1195369; AID1268962; AID1275913; AID1287517; AID1347711; AID1379902; AID1434427; AID1453412; AID1628036; AID1796552; AID1796595; AID1796755; AID1796855; AID1796980; AID1797276; AID1797360; AID1797528; AID1798598; AID1798769; AID1799734; AID1803440; AID238085; AID238208; AID238211; AID238247; AID238276; AID238309; AID238409; AID238536; AID238620; AID238753; AID238760; AID238770; AID238830; AID238957; AID239223; AID254240; AID258729; AID261579; AID263636; AID271037; AID271172; AID271710; AID272520; AID275807; AID281082; AID287698; AID300867; AID311023; AID317579; AID327758; AID331498; AID349605; AID367820; AID369271; AID414955; AID424442; AID427125; AID436563; AID47710; AID486932; AID496913; AID50350; AID50351; AID50352; AID50353; AID50354; AID50355; AID50356; AID50364; AID50366; AID50371; AID50373; AID50375; AID50377; AID50379; AID512001; AID552127; AID577526; AID578221; AID587130; AID597962; AID603067; AID603449; AID610535; AID612725; AID614105; AID620685; AID644380; AID697244; AID725955; AID743515
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)0.03920.00021.10608.3000AID47732; AID47736; AID47748; AID47749; AID47750
Carbonic anhydrase 2Homo sapiens (human)Ki6.38500.00000.72369.9200AID1061069; AID1062686; AID1140816; AID1142834; AID1154446; AID1188135; AID1190064; AID1194025; AID1195370; AID1240217; AID1268963; AID1275912; AID1278409; AID1287518; AID1347712; AID1379904; AID1434428; AID1453413; AID1628037; AID1796552; AID1796582; AID1796595; AID1796755; AID1796855; AID1796980; AID1797276; AID1797360; AID1797528; AID1798598; AID1798769; AID1799586; AID1799734; AID1803440; AID238084; AID238220; AID238223; AID238255; AID238300; AID238323; AID238437; AID238574; AID238635; AID238768; AID238772; AID238787; AID238850; AID238986; AID239240; AID254241; AID256963; AID258730; AID261580; AID263637; AID271038; AID271173; AID271711; AID272521; AID275808; AID281083; AID287699; AID300868; AID311024; AID317580; AID327759; AID331499; AID349606; AID367821; AID369272; AID414956; AID424443; AID427124; AID436564; AID437749; AID47898; AID47899; AID47900; AID47901; AID47902; AID47903; AID47904; AID47929; AID47931; AID47936; AID47938; AID47940; AID48088; AID48090; AID48093; AID486933; AID496914; AID512002; AID552128; AID577527; AID578222; AID587131; AID597963; AID603068; AID603448; AID610536; AID612726; AID614106; AID620686; AID644381; AID669115; AID697243; AID725956; AID743514
Carbonic anhydrase 3Homo sapiens (human)Ki187.97820.00022.010210.0000AID1798598; AID1803440; AID301578; AID327760; AID496915; AID603069
Cytochrome P450 3A4Homo sapiens (human)Ki0.05000.00011.41629.9000AID1154447; AID1154448
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.03800.00020.667710.0000AID47929; AID47936
Cytochrome P450 2C9 Homo sapiens (human)Ki0.05000.00031.684210.0000AID1154447
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.03800.00010.601710.0000AID47929; AID47936
Cannabinoid receptor 1Rattus norvegicus (Norway rat)Ki0.02300.00020.566510.0000AID496923
Carbonic anhydrase 4Homo sapiens (human)Ki31.94820.00021.97209.9200AID1796980; AID1798598; AID1803440; AID238575; AID272522; AID311026; AID327761; AID496916; AID597964
Carbonic anhydrase 6Homo sapiens (human)Ki39.05600.00011.47109.9200AID1798598; AID1798769; AID1803440; AID275806; AID311029; AID327764; AID369273; AID496919; AID552129
Carbonic anhydrase 5A, mitochondrialMus musculus (house mouse)Ki0.56450.00300.45603.0000AID1797528
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki0.03800.00020.590910.0000AID47929; AID47936
Delta-type opioid receptorMus musculus (house mouse)Ki0.61900.00000.53939.4000AID1188134; AID1188135
Cytochrome P450 2C19Homo sapiens (human)Ki0.05000.00010.830010.0000AID1154448
Delta-type opioid receptorRattus norvegicus (Norway rat)Ki0.03800.00000.60689.2330AID1188135
Mu-type opioid receptorRattus norvegicus (Norway rat)Ki1.20000.00000.38458.6000AID1188134
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki27.02610.00001.27259.9000AID1796582; AID1796980; AID1798598; AID1803440; AID256964; AID272523; AID311027; AID327762; AID496917; AID578223
Carbonic anhydraseMethanosarcina thermophilaKi0.17000.06000.97148.5000AID239145; AID239146
Carbonic anhydrase 7Homo sapiens (human)Ki26.91750.00021.37379.9000AID1060765; AID1796980; AID1798598; AID1799586; AID1803440; AID238256; AID272525; AID311030; AID327765; AID496920; AID603070
Carbonic anhydraseSaccharomyces cerevisiae S288CKi0.10300.08200.56098.7000AID367822
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.03800.00000.27869.0000AID1188135
Beta-carbonic anhydrase 1Mycobacterium tuberculosis H37RvKi0.87200.00483.38419.8400AID1798985; AID349607
Carbonic anhydrase 2Mycobacterium tuberculosis H37RvKi2.01000.00902.20969.8400AID437750
Carbonic anhydrase 9Homo sapiens (human)IC50 (µMol)0.05000.00030.63029.3900AID48294
Carbonic anhydrase 9Homo sapiens (human)Ki10.48970.00010.78749.9000AID1062685; AID1154447; AID1347713; AID1379905; AID1796595; AID1796755; AID1796855; AID1796980; AID1797276; AID1797360; AID1798598; AID1798769; AID1799734; AID1803440; AID238083; AID238224; AID238227; AID238438; AID238769; AID238774; AID238788; AID238987; AID239048; AID239102; AID239422; AID254246; AID258732; AID271039; AID271174; AID271712; AID272526; AID275809; AID281084; AID287700; AID300869; AID311031; AID317581; AID327766; AID331500; AID369274; AID48295; AID48296; AID48299; AID48300; AID48301; AID48302; AID48303; AID486934; AID496921; AID512003; AID598014; AID603450; AID610537; AID614107; AID620687; AID697242
Carbonic anhydrase, alpha family Hydrogenovibrio crunogenus XCL-2Ki0.02480.00250.32341.1000AID1268965
Carbonic anhydrase Cryptococcus neoformans var. grubiiKi1.20300.01000.73648.3470AID1237882; AID669116
Carbonic anhydraseMethanothermobacter thermautotrophicus str. Delta HKi105.00005.35005.35005.3500AID239250
Carbonic anhydraseCandida albicans SC5314Ki0.96800.01051.44448.3470AID1799266; AID424445; AID427122; AID669117
Carbonic anhydrase Anopheles gambiae (African malaria mosquito)Ki0.63000.00980.51174.3600AID1195371
Delta carbonic anhydraseConticribra weissflogiiKi0.45800.04960.99789.2000AID1061066
Carbonic anhydrase Nakaseomyces glabratus CBS 138Ki0.11200.00701.21749.1700AID744415
Carbonic anhydrase 13Homo sapiens (human)Ki53.65230.00031.23099.8000AID1803440; AID603071
Carbonic anhydrase 4Bos taurus (cattle)IC50 (µMol)0.38000.02100.20600.6200AID48112; AID48114
Carbonic anhydrase 4Bos taurus (cattle)Ki0.45750.00300.59349.6500AID1796755; AID1797276; AID1797528; AID238597; AID258731; AID48119; AID48120; AID48121; AID48122; AID48124; AID48132; AID48280; AID48282; AID48287; AID48288; AID48292
Carbonic anhydrase 15Mus musculus (house mouse)Ki0.09100.00091.884610.0000AID1798769; AID369275; AID496925
Carbonic anhydrase 13Mus musculus (house mouse)Ki11.53040.00021.39749.9000AID1796980; AID1798598; AID238301; AID272528; AID311033; AID327768; AID48310; AID496923
Carbonic anhydrase 14Homo sapiens (human)Ki26.27470.00021.50999.9000AID1796980; AID1798598; AID1803440; AID239703; AID272529; AID293194; AID311034; AID327769; AID486936; AID496924; AID610539; AID614109
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki26.93690.00001.34129.9700AID1796582; AID1796980; AID1798598; AID1803440; AID256965; AID272524; AID311028; AID327763; AID496918; AID578224
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase Brucella suis 1330Kinact0.05800.01700.86285.8700AID459696
cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7Homo sapiens (human)AC500.04680.039815.002550.0000AID743267
Carbonic anhydrase 12Homo sapiens (human)Kinact7.18570.00300.66749.6000AID1183268; AID299547; AID300757; AID328983; AID352790; AID386502; AID408472
Carbonic anhydrase 1Homo sapiens (human)Kinact1.20000.01000.93878.6000AID1183265; AID293811; AID299242; AID299538; AID300754; AID328974; AID352787; AID386500; AID408469
Carbonic anhydrase 2Homo sapiens (human)Kinact4.25600.00300.794610.0000AID1183266; AID293812; AID299243; AID299539; AID300755; AID328975; AID352788; AID386499; AID408470
Carbonic anhydrase 3Homo sapiens (human)Kinact6.30003.30006.16578.0000AID299540
Carbonic anhydrase 4Homo sapiens (human)Kinact15.00000.07402.39348.5900AID299541; AID328977
Carbonic anhydrase 6Homo sapiens (human)Kinact0.07900.00090.72615.3000AID299544; AID328980
Dipeptidyl peptidase 4Homo sapiens (human)Kinact0.03800.00800.01740.0380AID386499
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Kinact0.63000.02000.85809.4000AID299542; AID328978
Carbonic anhydrase 7Homo sapiens (human)Kinact0.02600.00020.28525.7300AID299545; AID328981
Carbonic anhydrase 9Homo sapiens (human)Kinact6.29380.00500.31976.6700AID1183267; AID293813; AID299546; AID300756; AID328982; AID352789; AID386501; AID408471
Carbonic anhydrase 13Mus musculus (house mouse)Kinact0.02300.01300.56698.2300AID299548; AID328984
Carbonic anhydrase 14Homo sapiens (human)Kinact0.34500.00021.44958.5900AID299549; AID328985
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Kinact0.02100.00900.92319.0400AID299543; AID328979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (130)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 13Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (70)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 13Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 13Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 13Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Bos taurus (cattle)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (50)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
myelin sheathCarbonic anhydrase 13Homo sapiens (human)
intracellular membrane-bounded organelleCarbonic anhydrase 13Homo sapiens (human)
cytoplasmCarbonic anhydrase 13Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
side of membraneCarbonic anhydrase 4Bos taurus (cattle)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (596)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID300867Inhibition of human cloned CA1 by CO2 hydration method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID327765Inhibition of human full length carbonic anhydrase 7 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID603069Inhibition of human recombinant cytosolic carbonic anhydrase 3 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms.
AID239102Inhibitory constant against catalytic domain of human carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID778725Inhibition of recombinant Leishmania donovani chagasi beta-carbonic anhydrase expressed in baculovirus infected insect Sf9 cells incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis.
AID1434428Inhibition of human carbonic anhydrase 2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID1240215Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase by CO2 hydration assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1190064Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3
Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID275807Inhibition of human recombinant cytosolic isozyme CA I by stopped-flow CO2 hydrase method2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID233702Selectivity ratio, inhibition (Ki) of human carbonic anhydrase IX compared to human carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID239250Inhibitory activity against beta carbonic anhydrase (Cab) from Methanobacterium thermoautotrophicum2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID238256Ki value against human carbonic anhydrase VII2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID1195371Inhibition of Anopheles gambiae carbonic anhydrase pre-incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID369271Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1188134Inhibition of human recombinant Carbonic anhydrase 1 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID552128Inhibition of human recombinant CA2 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID238770Inhibitory activity against human carbonic anhydrase I expressed in Escherichia coli BL212004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID349606Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID408471Inhibition of human cloned CA9 catalytic domain by stopped flow CO2 hydration assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID496923Inhibition of mouse carbonic anhydrase 13 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID300754Inhibition of human recombinant CA1 by CO2 hydration stopped flow assay2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.
AID1240214Inhibition of Nostoc commune gamma carbonic anhydrase by CO2 hydration assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID424445Inhibition of Candida albicans recombinant Carbonic anhydrase pre-incubated for 15 mins by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids.
AID1237875Selectivity ratio of Ki for human alpha-carbonic anhydrase 2 to Ki for Leishmania donovani chagasi beta-carbonic anhydrase2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties.
AID311025Inhibition of human carbonic anhydrase 32007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID697242Inhibition of human recombinant CA9 catalytic domain preincubated for 15 mins by stopped-flow CO2 hydration assay2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Development of potent carbonic anhydrase inhibitors incorporating both sulfonamide and sulfamide groups.
AID1347714Inhibition of human carbonic anhydrase 12 by stopped-flow CO2 hydration assay
AID1061169Inhibition of recombinant Methanosarcina thermophila gamma-CA CAM by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID255389Selectivity is measured as ratio of Ki value of Carbonic anhydrase II to that of Carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID299542Inhibition of human CA5A2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID327768Inhibition of mouse full length carbonic anhydrase 13 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID1183268Inhibition of human cloned CA12 catalytic domain pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID311028Inhibition of human carbonic anhydrase 5B2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID486934Inhibition of human cloned carbonic anhydrase 9 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486934Inhibition of human cloned carbonic anhydrase 9 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID261579Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID299547Inhibition of human CA122007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID299540Inhibition of human CA32007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID239284Inhibitory activity against catalytic domain of human carbonic anhydrase XII2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.
AID47929Inhibition of human carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits.
AID239240Inhibitory potency against human cloned Carbonic anhydrase II expressed in Escherichia coli strain BL212005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX.
AID238224Inhibitory constant against human Carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID238957Inhibitory activity against human carbonic anhydrase I at 0.09 uM2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID272520Inhibition of human cloned CA1 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID612725Inhibition of human recombinant carbonic anhydrase 1 at pH 7.5 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID610538Inhibition of human recombinant carbonic anhydrase 12 preincubated for 15 mins by CO2 hydration method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: Solution and X-ray crystallographic studies.
AID1268962Inhibition of recombinant human carbonic anhydrase-1 by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID238768Inhibitory activity against Carbonic anhydrase II2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID1061067Inhibition of Porphyromonas gingivalis recombinant gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID614109Inhibition of human cloned full length carbonic anhydrase 14 preincubated for 15 mins by stopped flow CO2 hydration assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID271037Inhibition of human cloned CA1 by CO2 hydration assay2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID300871Selectivity ratio of Ki for human cloned CA1 to Ki for human cloned catalytic domain CA92007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID352789Inhibition of human CA9 catalytic domain by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII.
AID50371Inhibitory activity against human cloned carbonic anhydrase isozyme I by esterase assay method.2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
AID1194026Inhibition of recombinant Methanosarcina thermophila gamma-carbonic anhydrase by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID620689Selectivity ratio of Ki for human carbonic anhydrase 1 to Ki for human recombinant carbonic anhydrase 9 catalytic domain2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.
AID299242Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID578221Inhibition of human recombinant CA1 cytosolic isoform by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
(R)-/(S)-10-camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases.
AID48088Inhibitory activity against human carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID1183267Inhibition of human cloned CA9 catalytic domain pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID47903Inhibitory activity against human cloned carbonic anhydrase II (hCA II)2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV.
AID328976Inhibition of human full length carbonic anhydrase 32008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID552130Inhibition of Stylophora pistillata carbonic anhydrase by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID238301Ki value against murine carbonic anhydrase XIII2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID598014Inhibition of human recombinant CA9 catalytic domain by CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action.
AID272528Inhibition of murine CA13 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1278413Inhibition of recombinant Colwellia psychrerythraea gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID293812Inhibition of human recombinant CA2 by stopped flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID47898Inhibition of human cytosolic isozyme Carbonic anhydrase II at 20 degree C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID327767Inhibition of human catalytic domain carbonic anhydrase 12 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID238220Inhibitory constant against human Carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID238536Inhibitory activity against human carbonic anhydrase I (hCAI)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.
AID311030Inhibition of human carbonic anhydrase 72007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID256963Inhibitory activity against human recombinant cytosolic CA22005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID311032Inhibition of human carbonic anhydrase 122007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID669119Inhibition of GST-tagged Malassezia globosa ATCC 96807/CBS 7966 MG-CA expressed in Escherichia coli BL21(DE3) cells preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID512004Inhibition of human cloned catalytic domain of CA12 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512004Inhibition of human cloned catalytic domain of CA12 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID327758Inhibition of human full length carbonic anhydrase 1 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID697241Inhibition of human recombinant CA12 catalytic domain preincubated for 15 mins by stopped-flow CO2 hydration assay2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Development of potent carbonic anhydrase inhibitors incorporating both sulfonamide and sulfamide groups.
AID299544Inhibition of human CA62007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID311027Inhibition of human carbonic anhydrase 5A2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID414955Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration method2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID50351In vitro inhibitory activity against human carbonic anhydrase I (hCAI)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.
AID1237874Selectivity ratio of Ki for human alpha-carbonic anhydrase 2 to Ki for Brucella suis beta-carbonic anhydrase 22015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties.
AID238223Inhibitory constant against human Carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID263639Selectivity for Helicobacter pylori recombinant CA over human recombinant CA22006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID1194024Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1347711Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydration assay
AID275809Inhibition of catalytic domain of human recombinant CA IX2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID1142838Inhibition of Helicobacter pylori carbonic anhydrase by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID238597Inhibitory activity against bovine carbonic anhydrase IV (bCAIV)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.
AID50355Inhibitory activity against human cloned carbonic anhydrase I (hCA I)2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV.
AID577530Inhibition of Brucella suis carbonic anhydrase II by spectrophotometry at pH 8.32011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID275806Inhibition of full length human recombinant CA VI2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID367820Inhibition of human recombinant CA1 by stopped-flow CO2 hydrase assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID369273Inhibition of human full length recombinant carbonic anhydrase 6 by stopped flow CO2 hydrase assay2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID424443Inhibition of human recombinant cytosolic carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids.
AID1154448Inhibition of human cloned transmembrane tumor-associated catalytic domain of carbonic anhydrase 12 preincubated for 15 mins by stopped flow CO2 hydration assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID299552Inhibition of Methanosarcina thermophila gamma CA2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID272522Inhibition of human cloned CA4 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1194028Inhibition of recombinant Nostoc commune gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID486932Inhibition of human cloned carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486932Inhibition of human cloned carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID271039Inhibition of human cloned CA9 catalytic domain by CO2 hydration assay2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID386501Inhibition of human cloned CA9 catalytic domain by stopped-flow CO2 hydration method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID239703Inhibitory constant against human carbonic anhydrase XIV in CO2 hydrase assay2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID50366Inhibition constant determined against human cloned carbonic anhydrase I2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID271175Selectivity for human recombinant carbonic anhydrase 9 over carbonic anhydrase 22006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID424442Inhibition of human recombinant cytosolic carbonic anhydrase 1 preincubated for 15 mins by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids.
AID697244Inhibition of full length human CA1 cytosolic isoform preincubated for 15 mins by stopped-flow CO2 hydration assay2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Development of potent carbonic anhydrase inhibitors incorporating both sulfonamide and sulfamide groups.
AID299543Inhibition of human CA5B2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID408470Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID1379905Inhibition of recombinant human carbonic anhydrase 9 catalytic domain preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors.
AID50345Inhibitory activity against human carbonic anhydrase I was determined2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
AID244228Ratio of inhibitory potency against carbonic anhydrase II to that of inhibitory potency against carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX.
AID408472Inhibition of human cloned CA12 catalytic domain by stopped flow CO2 hydration assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID299550Inhibition of Helicobacter pylori alpha CA2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID47938Inhibitory activity against human recombinant carbonic anhydrase II2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects.
AID470873Inhibition of carbonic anhydrase 2 assessed as inhibition of carbon dioxide hydration2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
A QSAR study on relationship between structure of sulfonamides and their carbonic anhydrase inhibitory activity using the eigenvalue (EVA) method.
AID281086Selectivity ratio of human CA9 over human CA22007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID1237871Selectivity ratio of Ki for human alpha-carbonic anhydrase 1 to Ki for Leishmania donovani chagasi beta-carbonic anhydrase2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties.
AID281082Inhibition of human recombinant isozyme CA1 by CO2 hydration method2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID48124Inhibitory activity against carbonic anhydrase isolated from bovine lung microsome (bCA IV)2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV.
AID620688Inhibition of human carbonic anhydrase 12-catalyzed CO2 hydration activity by stopped flow assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.
AID238259Ratio against Carbonic anhydrase II to Carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID1061066Inhibition of Thalassiosira weissflogii delta carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID239146Inhibitory activity against alpha carbonic anhydrase (Zn-Cam) from Methanosarcina thermophila2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID258733Inhibitory activity against cloned human CA122006Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
AID48287Inhibitory activity against carbonic anhydrase IV from bovine lung microsomes2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID261581Inhibition of Helicobacter pylori recombinant carbonic anhydrase by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID287698Inhibition of human recombinant carbonic anhydrase 1 by CO2 hydration method2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
AID48294Inhibitory activity against human carbonic anhydrase IX was determined2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
AID669115Inhibition of human carbonic anhydrase 2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID238085Inhibition constant against human (cloned) isozyme (hCA I) by the CO2 hydration method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID238247Ki value against human carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID496920Inhibition of human carbonic anhydrase 7 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID367821Inhibition of human recombinant CA2 by stopped-flow CO2 hydrase assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID1434430Inhibition of Vibrio cholerae Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID238255Ki value against human carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID238788Inhibitory activity against human carbonic anhydrase IX expressed in Escherichia coli BL212004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID349608Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 3 expressed in Escherichia coli BL21 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID299243Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID1061170Inhibition of Porphyromonas gingivalis gamma-carbonic anhydrase expressed in Escherichia coli preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID1204095Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-2 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-122015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID496917Inhibition of human carbonic anhydrase 5A by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID50373Inhibitory activity against human recombinant carbonic anhydrase I2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects.
AID603454Selectivity ratio of Ki for human full length cytosolic isoform of carbonic anhydrase 2 to Ki for human recombinant catalytic domain of carbonic anhydrase 92011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII.
AID577531Inhibition of Brucella suis carbonic anhydrase I by spectrophotometry at pH 8.32011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID327769Inhibition of human full length carbonic anhydrase 14 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID301578Inhibition of human recombinant CA 3 assessed as CO2 hydration by stopped flow kinetic assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.
AID409947Inhibition of human recombinant MAOB at 1 mM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID271038Inhibition of human cloned CA2 by CO2 hydration assay2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID408469Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID1237883Selectivity ratio of Ki for human alpha-carbonic anhydrase 1 to Ki for Cryptococcus neoformans var. grubii beta-carbonic anhydrase2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties.
AID311024Inhibition of human carbonic anhydrase 22007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID299548Inhibition of mouse CA132007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID577527Inhibition of human carbonic anhydrase II by spectrophotometry at pH 7.52011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID578224Inhibition of human recombinant CA5B mitochondrial isoform by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
(R)-/(S)-10-camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases.
AID271040Inhibition of human cloned CA12 catalytic domain by CO2 hydration assay2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID1062687Inhibition of human CA1 cytosolic isoform after 15 mins by stopped-flow CO2 hydration assay2014European journal of medicinal chemistry, Jan, Volume: 71Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID47750Inhibitory activity against carbonic anhydrase II2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.
AID1237869Selectivity ratio of Ki for human alpha-carbonic anhydrase 1 to Ki for Brucella suis beta-carbonic anhydrase 12015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties.
AID512002Inhibition of human cloned CA2 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512002Inhibition of human cloned CA2 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1628036Inhibition of full length human cytosolic carbonic anhydrase 1 preincubated for 15 mins by stop flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID328977Inhibition of human full length carbonic anhydrase 42008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1204093Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-2 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-92015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID612732Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 2 at pH 8.3 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID258730Inhibitory activity against cloned human CA22006Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
AID1154447Inhibition of human cloned transmembrane tumor-associated catalytic domain of carbonic anhydrase 9 preincubated for 15 mins by stopped flow CO2 hydration assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID238850Inhibitory activity against human carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.
AID437750Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 2 encoded by RV3588c by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID614108Inhibition of human cloned carbonic anhydrase 12 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID48310Inhibitory activity against murine carbonic anhydrase XIII (mCA XIII) by using CO2 hydrase assay method2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.
AID1453411Inhibition of Burkholderia pseudomallei beta-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID620692Selectivity ratio of Ki for human carbonic anhydrase 2 to Ki for human recombinant carbonic anhydrase 12 catalytic domain2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.
AID369272Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID47901Inhibitory activity against Human carbonic anhydrase II2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID620691Selectivity ratio of Ki for human carbonic anhydrase 2 to Ki for human recombinant carbonic anhydrase 9 catalytic domain2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.
AID1291363Inhibition of recombinant Vibrio cholerae gamma-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Comparison of the sulfonamide inhibition profiles of the α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID271710Inhibition of human cloned CA1 by CO2 hydration method2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID711662Selectivity ratio of Ki for human CA2 to Ki for human CA92012European journal of medicinal chemistry, Oct, Volume: 56Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1275913Inhibition of human Carbonic anhydrase1 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1347713Inhibition of human carbonic anhydrase 9 by stopped-flow CO2 hydration assay
AID238467Inhibition constant against human carbonic anhydrase XII2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID238323Inhibitory activity against human Carbonic anhydrase II2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.
AID48302Inhibitory activity against human carbonic anhydrase IX2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID50350Inhibition of cloned human cytosolic isozyme Carbonic anhydrase I2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID293194Inhibition of human recombinant CA14 by CO2 hydration assay2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides.
AID47936Inhibition of human carbonic anhydrase II2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
AID1453413Inhibition of human carbonic anhydrase-2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID272521Inhibition of human cloned CA2 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID743514Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID317581Inhibition of human CA9 catalytic domain by CO2 hydration method2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID238769Inhibitory activity against Carbonic anhydrase IX2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID612731Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 1 at pH 8.3 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID367822Inhibition of Saccharomyces cerevisiae recombinant CA expressed in Escherichia coli by stopped-flow CO2 hydrase assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID50377Inhibitory activity against human carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID48309Inhibition of murine mitochondrial isozyme Carbonic anhydrase V at 20 degrees C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID272527Inhibition of catalytic domain of human cloned CA12 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID238987Inhibitory activity against human carbonic anhydrase IX at 0.09 uM2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID238208Inhibitory constant against human Carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID311026Inhibition of human carbonic anhydrase 42007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID50364Inhibition of human carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits.
AID496915Inhibition of human carbonic anhydrase 3 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID271714Selectivity for human CA9 over CA22006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID328983Inhibition of human catalytic domain carbonic anhydrase 122008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID597964Inhibition of human CA4 by CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action.
AID669122Antimicrobial activity against Malassezia pachydermatis CBS 6536 after 7 days2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID1379904Inhibition of recombinant human full-length carbonic anhydrase 2 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors.
AID587130Inhibition of human carbonic anhydrase 1 after 15 mins by CO2 hydrase assay at pH 7.52011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID512001Inhibition of human cloned CA1 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512001Inhibition of human cloned CA1 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1268965Inhibition of recombinant Thiomicrospira crunogena XCL-2 carbonic anhydrase by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID1278409Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by CO2 hydrase stopped flow assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID238227Inhibitory constant against human Carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID587131Inhibition of human carbonic anhydrase 2 after 15 mins by CO2 hydrase assay at pH 7.52011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID50379Inhibitory activity against human carbonic anhydrase I (hCA I) by using esterase assay method2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.
AID512003Inhibition of human cloned catalytic domain of CA9 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512003Inhibition of human cloned catalytic domain of CA9 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID349605Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID427123Inhibition of Cryptococcus neoformans recombinant Can2 by stopped-flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID299545Inhibition of human CA72007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID424444Inhibition of Cryptococcus neoformans recombinant Carbonic anhydrase 2 pre-incubated for 15 mins by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids.
AID287700Inhibition of human recombinant carbonic anhydrase 9 by CO2 hydration method2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
AID1154445Inhibition of human cloned cytosolic carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID47749Inhibitory activity against human carbonic anhydrase II was determined2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
AID47900Inhibition constant evaluated for the inhibition of human CA II (Carbonic anhydrase II)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID743515Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID254246Inhibitory activity against catalytic domain of human cloned Carbonic anhydrase IX by the CO2 hydration method2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID48299Inhibition constant determined against catalytic domain of human cloned carbonic anhydrase IX2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID1140817Inhibition of human carbonic anhydrase 1-catalyzed CO2 hydration preincubated for 10 mins by stopped-flow assay2014Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10
Carbonic anhydrase inhibitors. Inhibition of human cytosolic isoforms I and II with (reduced) Schiff's bases incorporating sulfonamide, carboxylate and carboxymethyl moieties.
AID47902Inhibitory activity against human recombinant carbonic anhydrase II (CA2)2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
AID610536Inhibition of human recombinant cytosolic carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: Solution and X-ray crystallographic studies.
AID331500Inhibition of human cloned carbonic anhydrase 9 by CO2 hydration stopped-flow assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID1142834Inhibition of human carbonic anhydrase-2 by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID327763Inhibition of human full length carbonic anhydrase 5B by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID1188138Inhibition of Porphyromonas gingivalis Gamma-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID239145Inhibitory activity against alpha carbonic anhydrase (Co-Cam) from Methanosarcina thermophila2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID47748Inhibitory activity of compound against human carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.
AID238409Inhibition constant against human carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID48288Inhibition of bovine carbonic anhydrase IV (CA4) from bovine lung microsomes2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action.
AID577526Inhibition of human carbonic anhydrase I by spectrophotometry at pH 7.52011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID238635Inhibitory activity against cytosolic human carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID486935Inhibition of human cloned carbonic anhydrase 12 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486935Inhibition of human cloned carbonic anhydrase 12 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID238760Binding affinity towards human cloned carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID47940Inhibitory activity against human carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID598015Inhibition of human recombinant CA12 catalytic domain by CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action.
AID327761Inhibition of human full length carbonic anhydrase 4 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID254241Inhibitory activity against human cloned Carbonic anhydrase II by the CO2 hydration method2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID1188137Inhibition of Porphyromonas gingivalis Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID711212Inhibition of recombinant Vibrio cholerae carbonic anhydrase expressed in Escherichia coli (DE3) preincubated for 15 mins by stopped-flow CO2 hydrase assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID369275Inhibition of mouse recombinant carbonic anhydrase 15 by stopped flow CO2 hydrase assay2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1188136Inhibition of Helicobacter pylori Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID48119Inhibition of bovine membrane bound isozyme carbonic anhydrase IV isolated from microsomes at 20 degree C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID610539Inhibition of human recombinant carbonic anhydrase 14 preincubated for 15 mins by CO2 hydration method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: Solution and X-ray crystallographic studies.
AID587132Inhibition of Leptonychotes weddellii alpha-carbonic anhydrase after 15 mins by CO2 hydrase assay at pH 7.52011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID610535Inhibition of human recombinant cytosolic carbonic anhydrase 1 preincubated for 15 mins by CO2 hydration method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: Solution and X-ray crystallographic studies.
AID328982Inhibition of human catalytic domain carbonic anhydrase 92008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID331499Inhibition of human recombinant carbonic anhydrase 2 by CO2 hydration stopped-flow assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID597962Inhibition of human CA1 by CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action.
AID496918Inhibition of human carbonic anhydrase 5B by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID669120Antimicrobial activity against Malassezia furfur CBS 9569 after 7 days2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID239126Inhibitory constant against catalytic domain of human carbonic anhydrase XII2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID669117Inhibition of Candida albicans CaNce103 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID263636Inhibition of human recombinant CA12006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID552127Inhibition of human recombinant CA1 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID620687Inhibition of human carbonic anhydrase 9-catalyzed CO2 hydration activity by stopped flow assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.
AID238753Inhibitory activity against Carbonic anhydrase I2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID238787Inhibitory activity against human carbonic anhydrase II expressed in Escherichia coli BL212004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID238438Inhibition constant against human carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID244399Selectivity ratio of Inhibitory constant against human carbonic anhydrase II to carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID281084Inhibition of catalytic domain of human recombinant isozyme CA9 by CO2 hydration method2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID48301Inhibitory activity against human carbonic anhydrase IX2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID4773250% inhibition of human carbonic anhydrase II assayed by CO2 hydration catalyzed by human erythrocytes1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophenesulfonamide derivatives with ocular hypotensive activity.
AID1240216Inhibition of Methanosarcina thermophila recombinant gamma carbonic anhydrase by stopped flow CO2 hydrase assay method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID238574Inhibitory activity against human carbonic anhydrase II (hCAII)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.
AID603067Inhibition of human recombinant cytosolic carbonic anhydrase 1 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms.
AID293813Inhibition of human recombinant CA9 by stopped flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID603070Inhibition of human recombinant cytosolic carbonic anhydrase 7 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms.
AID496914Inhibition of human carbonic anhydrase 2 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID1628037Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stop flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID1453412Inhibition of human carbonic anhydrase-1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID1434429Inhibition of Burkholderia pseudomallei Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID300868Inhibition of human cloned CA2 by CO2 hydration method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID614105Inhibition of human cloned carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID317583Selectivity for human CA9 over human CA22008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID50375Inhibitory activity against human carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID327766Inhibition of human catalytic domain carbonic anhydrase 9 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID603068Inhibition of human recombinant cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms.
AID311034Inhibition of human carbonic anhydrase 142007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID238083Inhibition constant against human cloned isozyme (hCA IX) by CO2 hydration method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID281085Selectivity ratio of human CA9 over human CA12007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID1237882Inhibition of Cryptococcus neoformans var. grubii beta-carbonic anhydrase incubated for 15 mins prior to testing by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties.
AID272529Inhibition of human cloned CA14 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1142837Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-2 assessed as CO2 hydrase activity by stopped-flow assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID271172Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID1195370Inhibition of human carbonic anhydrase 2 pre-incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID1268963Inhibition of recombinant human carbonic anhydrase-2 by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID1204092Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-1 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-92015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID603452Selectivity ratio of Ki for human full length cytosolic isoform of carbonic anhydrase 1 to Ki for human recombinant catalytic domain of carbonic anhydrase 92011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII.
AID620685Inhibition of human carbonic anhydrase 1-catalyzed CO2 hydration activity by stopped flow assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.
AID1154446Inhibition of human cloned cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID1278411Inhibition of Nostoc commune gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID436564Inhibition of human recombinant CA2 by stopped-flow CO2 assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID486936Inhibition of human full length carbonic anhydrase 14 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486936Inhibition of human full length carbonic anhydrase 14 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID48121Inhibitory activity against bovine carbonic anhydrase IV (CA4), obtained from bovine lung microsomes2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
AID436565Inhibition of cloned Stylophora pistillata alpha-CA expressed in human HEK293 cells by stopped-flow CO2 assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID725955Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID603448Inhibition of human full length cytosolic isoform of carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration stopped-flow assay2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII.
AID1287518Inhibition of human carbonic anhydrase 2 incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID50356Inhibitory activity against human cloned isoenzyme carbonic anhydrase I (hCA I), by esterase method.2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II with sulfamide derivatives.
AID327762Inhibition of human full length carbonic anhydrase 5A by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID272523Inhibition of human cloned CA5A by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1204094Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-1 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-122015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID299551Inhibition of Helicobacter pylori beta CA2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID47736In vitro inhibition of human Carbonic Anhydrase II1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Topically active carbonic anhydrase inhibitors. 1. O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide.
AID300757Inhibition of human CA12 catalytic domain by CO2 hydration stopped flow assay2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.
AID243098Ratio of inhibitory activity of human cytosolic carbonic anhydrase II to tumor associated carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID1434427Inhibition of recombinant human carbonic anhydrase 1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID238437Inhibition constant against human carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID271713Selectivity for human CA9 over CA12006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID331498Inhibition of human recombinant carbonic anhydrase 1 by CO2 hydration stopped-flow assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID352790Inhibition of human CA12 catalytic domain by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII.
AID669123Antimicrobial activity against Malassezia globosa CBS 7966 after 7 days2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID386499Inhibition of human cloned CA2 by stopped-flow CO2 hydration method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID620686Inhibition of human carbonic anhydrase 2-catalyzed CO2 hydration activity by stopped flow assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.
AID1142833Inhibition of human carbonic anhydrase-1 by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID610537Inhibition of human recombinant carbonic anhydrase 9 preincubated for 15 mins by CO2 hydration method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: Solution and X-ray crystallographic studies.
AID272526Inhibition of catalytic domain of human cloned CA9 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID50352Inhibition constant evaluated for the inhibition of human CA I (Carbonic anhydrase I)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID614106Inhibition of human cloned carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID311031Inhibition of human carbonic anhydrase 92007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID1268964Inhibition of recombinant Sulfurihydrogenibium yellowstonense YO3AOP1 carbonic anhydrase by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID271173Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID552131Inhibition of Stylophora pistillata carbonic anhydrase 2 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID597963Inhibition of human CA2 by CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action.
AID386500Inhibition of human cloned CA1 by stopped-flow CO2 hydration method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID459696Inhibition of Brucella suis CA1 expressed in Escherichia coli BL21(DE3) by stopped-flow CO2-hydration assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis.
AID1379906Inhibition of recombinant human carbonic anhydrase 12 catalytic domain preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors.
AID263638Inhibition of Helicobacter pylori recombinant CA2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID287699Inhibition of human recombinant carbonic anhydrase 2 by CO2 hydration method2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
AID1061068Inhibition of Leishmania donovani chagasi recombinant beta-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID311023Inhibition of human carbonic anhydrase 12007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID239223Inhibitory potency against human cloned Carbonic anhydrase I expressed in Escherichia coli strain BL212005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX.
AID299249Inhibition of Helicobacter pylori alpha carbonic anhydrase by stopped-flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID1194025Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1140816Inhibition of human carbonic anhydrase 2-catalyzed CO2 hydration preincubated for 10 mins by stopped-flow assay2014Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10
Carbonic anhydrase inhibitors. Inhibition of human cytosolic isoforms I and II with (reduced) Schiff's bases incorporating sulfonamide, carboxylate and carboxymethyl moieties.
AID48280Inhibitory activity against bovine carbonic anhydrase isozyme IV isolated from bovine lung microsomes, by esterase assay method.2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
AID50354Inhibitory activity against human recombinant carbonic anhydrase I (CA1)2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
AID743512Inhibition of Sulfurihydrogenibium yellowstonense YO3AOP1 recombinant carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID299549Inhibition of human CA142007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID238774Binding affinity towards human cloned carbonic anhydrase IX2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID300870Selectivity ratio of Ki for human cloned CA1 to Ki for human cloned catalytic domain CA92007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID293811Inhibition of human recombinant CA1 by stopped flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID261582Selectivity ratio for human carbonic anhydrase 2 over Helicobacter pylori carbonic anhydrase2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID271711Inhibition of human cloned CA2 by CO2 hydration method2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID1628038Inhibition of recombinant Plasmodium falciparum eta-carbonic anhydrase (181 to 538 residues) expressed in Escherichia coli artic express (DE3) preincubated for 15 mins by stop flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID299546Inhibition of human CA9 catalytic domain2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID275808Inhibition of human recombinant cytosolic isozyme CA II by stopped-flow CO2 hydrase method2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID293193Inhibition of human recombinant CA12 by CO2 hydration assay2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides.
AID50344Inhibitory activity of compound against human carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.
AID48282Inhibitory activity against bovine carbonic anhydrase IV from lung microsomes2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects.
AID644381Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID578223Inhibition of human recombinant CA5A mitochondrial isoform by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
(R)-/(S)-10-camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases.
AID299539Inhibition of human CA22007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID238986Inhibitory activity against human carbonic anhydrase II at 0.01 uM2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID552129Inhibition of human recombinant CA6 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID496922Inhibition of human carbonic anhydrase 12 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID47931Inhibition constant (Ki) against human cloned carbonic anhydrase II (CAH)2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID48300Inhibitory activity against human cloned carbonic anhydrase isozyme IX, by CO2 hydrase assay method.2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
AID725956Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1060765Inhibition of human recombinant carbonic anhydrase 7 preincubated for 15 mins by stopped flow CO2 hydration assay2014European journal of medicinal chemistry, Jan, Volume: 71Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.
AID603453Selectivity ratio of Ki for human full length cytosolic isoform of carbonic anhydrase 1 to Ki for human recombinant catalytic domain of carbonic anhydrase 122011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII.
AID328975Inhibition of human full length carbonic anhydrase 22008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID496924Inhibition of human carbonic anhydrase 14 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID232688Selectivity ratio of KI, human carbonic anhydrase II (hCA II), to that of KI, mouse carbonic anhydrase V (mCA V)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID1183266Inhibition of human cloned CA2 pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID327764Inhibition of human full length carbonic anhydrase 6 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID258731Inhibitory activity against CA4 isolated from bovine lung microsomes2006Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
AID271174Inhibition of human recombinant carbonic anhydrase 9 by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID744415Inhibition of recombinant full length Candida glabrata NCE103 expressed in Escherichia coli BL21 preincubated for 15 mins by stopped-flow CO2 hydrase assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID238084Inhibition constant against human (cloned) isozyme (hCA II) by CO2 hydration method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID414956Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration method2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID311029Inhibition of human carbonic anhydrase 62007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID317582Selectivity for human CA9 over human CA12008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID1190065Inhibition of Plasmodium falciparum Eta-carbonic anhydrase pre-incubated for 15 mins before CO2 substrate addition by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3
Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID1195369Inhibition of human carbonic anhydrase 1 pre-incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID1278410Inhibition of Porphyromonas gingivalis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID327759Inhibition of human full length carbonic anhydrase 2 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID238316Ki value against human carbonic anhydrase XII (hCA XII)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID1240217Inhibition of human recombinant carbonic anhydrase-2 by stopped flow CO2 hydrase assay method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID47904Inhibitory activity against human cloned isoenzyme carbonic anhydrase II (hCA II), by esterase method.2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II with sulfamide derivatives.
AID239048Inhibitory activity against membrane bound tumor associated human carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID48296Inhibitory activity against human tumor-associated transmembrane carbonic anhydrase IX.2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Carbonic anhydrase inhibitors: the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides.
AID496919Inhibition of human carbonic anhydrase 6 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID496913Inhibition of human carbonic anhydrase 1 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID254240Inhibitory activity against human cloned Carbonic anhydrase I by the CO2 hydration method2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID328978Inhibition of human full length carbonic anhydrase 5A2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID328980Inhibition of human full length carbonic anhydrase 62008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID603451Inhibition of human recombinant catalytic domain of carbonic anhydrase 12 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII.
AID317580Inhibition of human cloned CA2 by CO2 hydration method2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID48132Inhibition constant against bovine Carbonic anhydrase IV, isolated from lung microsomes2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID386502Inhibition of human cloned CA12 catalytic domain by stopped-flow CO2 hydration method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID352787Inhibition of human recombinant CA1 by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII.
AID427122Inhibition of Candida albicans recombinant Nce103 by stopped-flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID238309Inhibitory activity against human Carbonic anhydrase I2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.
AID331501Selectivity ratio of Ki for human recombinant carbonic anhydrase 2 to Ki for human cloned carbonic anhydrase 92008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID603455Selectivity ratio of Ki for human full length cytosolic isoform of carbonic anhydrase 2 to Ki for human recombinant catalytic domain of carbonic anhydrase 122011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII.
AID238300Ki value against human carbonic anhydrase II (hCA II)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID1347712Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydration assay
AID1275911Inhibition of Vibrio cholerae alpha-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID328984Inhibition of mouse full length carbonic anhydrase 132008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1142836Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-1 assessed as CO2 hydrase activity by stopped-flow assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1062686Inhibition of human CA2 cytosolic isoform after 15 mins by stopped-flow CO2 hydration assay2014European journal of medicinal chemistry, Jan, Volume: 71Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID644379Inhibition of GST-tagged astrosclera willeyana Astrosclerin-3 expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID1275912Inhibition of human Carbonic anhydrase2 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1194027Inhibition of recombinant Porphyromonas gingivalis gamma-carbonic anhydrase by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID603449Inhibition of human full length cytosolic isoform of carbonic anhydrase 1 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII.
AID486933Inhibition of human cloned carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486933Inhibition of human cloned carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID327760Inhibition of human full length carbonic anhydrase 3 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID1190063Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3
Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID256966Selectivity ratio for human CA VB over human CA22005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID1275910Inhibition of Vibrio cholerae beta-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID238276Ki value against human carbonic anhydrase I (hCA I)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID352788Inhibition of human recombinant CA2 by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII.
AID271712Inhibition of human cloned CA9 catalytic domain by CO2 hydration method2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID1237884Selectivity ratio of Ki for human alpha-carbonic anhydrase 2 to Ki for Cryptococcus neoformans var. grubii beta-carbonic anhydrase2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties.
AID1188135Inhibition of human recombinant Carbonic anhydrase 2 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID1287517Inhibition of human carbonic anhydrase 1 incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID743513Inhibition of Helicobacter pylori recombinant alpha carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID328974Inhibition of human full length carbonic anhydrase 12008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID243090Ratio of inhibition of carbonic anhydrase IV in human to that of carbonic anhydrase IV in bovine2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.
AID48112Inhibitory activity of compound against bovine carbonic anhydrase IV2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.
AID496921Inhibition of human carbonic anhydrase 9 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID238620Inhibitory activity against cytosolic human carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID238772Binding affinity towards human cloned carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID1278412Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID258732Inhibitory activity against cloned human CA92006Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
AID697243Inhibition of full length human CA2 cytosolic isoform preincubated for 15 mins by stopped-flow CO2 hydration assay2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Development of potent carbonic anhydrase inhibitors incorporating both sulfonamide and sulfamide groups.
AID47710Inhibition of human recombinant carbonic anhydrase I (CA1)2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action.
AID244240Binding affinity ratio towards human cloned carbonic anhydrase II to that of human cloned carbonic anhydrase IX2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID578222Inhibition of human recombinant CA2 cytosolic isoform by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
(R)-/(S)-10-camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases.
AID48303Inhibitory activity against human carbonic anhydrase IX (hCA IX) by using CO2 hydrase assay method2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.
AID1061069Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID427124Inhibition of Helicobacter pylori beta-carbonic anhydrase by stopped-flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID300756Inhibition of human CA9 catalytic domain by CO2 hydration stopped flow assay2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.
AID256965Inhibitory activity against human recombinant mitochondrial isozyme CA VB2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID496925Inhibition of mouse carbonic anhydrase 15 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID620690Selectivity ratio of Ki for human carbonic anhydrase 1 to Ki for human recombinant carbonic anhydrase 12 catalytic domain2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.
AID244127Ratio of Ki for human carbonic anhydrases II and IX2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID48120In vitro inhibitory activity against bovine carbonic anhydrase IV (CAIV)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.
AID47899In vitro inhibitory activity against human carbonic anhydrase II (hCAII)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.
AID603071Inhibition of human recombinant cytosolic carbonic anhydrase 13 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms.
AID238575Inhibitory activity against human carbonic anhydrase IV (hCAIV)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.
AID1237870Selectivity ratio of Ki for human alpha-carbonic anhydrase 1 to Ki for Brucella suis beta-carbonic anhydrase 22015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties.
AID1183265Inhibition of human cloned CA1 pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID427125Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase method2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1204091Inhibition of recombinant human transmembrane, tumor-associated form of carbonic anhydrase-12 preincubated for 15 mins by stopped flow CO2 hydration assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID261580Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID612726Inhibition of human recombinant carbonic anhydrase 2 at pH 7.5 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID317579Inhibition of human cloned CA1 by CO2 hydration method2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID48093Inhibition of human recombinant carbonic anhydrase II (CA2)2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action.
AID300755Inhibition of human recombinant CA2 by CO2 hydration stopped flow assay2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.
AID349607Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase 1 encoded by Rv1284 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID409950Inhibition of human brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID299538Inhibition of human CA12007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID328985Inhibition of human full length carbonic anhydrase 142008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1204106Inhibition of recombinant Streptococcus mutans UA159 beta-carbonic anhydrase expressed in Escherichia coli Arctic cells preincubated for 15 mins by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Sulfonamide inhibition study of the β-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.
AID644380Inhibition of human recombinant carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID1062685Inhibition of human CA9 after 15 mins by stopped-flow CO2 hydration assay2014European journal of medicinal chemistry, Jan, Volume: 71Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID1287520Inhibition of recombinant Enterobacter sp. B13 beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID300869Inhibition of human cloned catalytic domain CA9 by CO2 hydration method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID496916Inhibition of human carbonic anhydrase 4 by stopped flow CO2 hydration method2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.
AID243011Selectivity ratio against human carbonic anhydrases II and XII2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID369274Inhibition of human recombinant carbonic anhydrase 9 catalytic domain by stopped flow CO2 hydrase assay2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID299541Inhibition of human CA42007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID165489Reduction in maximum Intra ocular pressure in the rabbit model of ocular hypertension, when treated with a minimum effective oral dose of 10 mg/Kg1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophenesulfonamide derivatives with ocular hypotensive activity.
AID669116Inhibition of Cryptococcus neoformans Can2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID328981Inhibition of human full length carbonic anhydrase 72008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID437749Inhibition of human recombinant CA2 by stopped-flow hydration assay2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID256964Inhibitory activity against human recombinant mitochondrial isozyme CA VA2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID48114Inhibitory activity against bovine carbonic anhydrase IV was determined2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
AID272524Inhibition of human cloned CA5B by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID669121Antimicrobial activity against Malassezia dermatis CBS 9145 after 7 days2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID48122Inhibitory activity against bovine carbonic anhydrase IV2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID726232Inhibition of Trypanosoma cruzi CL Brener recombinant alpha-carbonic anhydrase expressed in insect Sf9 cell Baculovirus system by stopped flow CO2 hydration assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID50353Inhibitory activity against Human carbonic anhydrase I2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID238830Inhibitory activity against human carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.
AID1062684Inhibition of human CA12 after 15 mins by stopped-flow CO2 hydration assay2014European journal of medicinal chemistry, Jan, Volume: 71Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID409952Inhibition of human brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID293814Selectivity for human recombinant CA9 over human recombinant CA22007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID48295Inhibition constant evaluated for the inhibition of human CA IX (Carbonic anhydrase IX)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID263637Inhibition of human recombinant CA22006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID1237873Selectivity ratio of Ki for human alpha-carbonic anhydrase 2 to Ki for Brucella suis beta-carbonic anhydrase 12015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties.
AID48292Inhibition constant evaluated for the inhibition of bovine CA IV (Carbonic anhydrase IV)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID414961Inhibition of Mycobacterium tuberculosis H37Rv recombinant beta-carbonic anhydrase 1 expressed in Escherichia coli BL21 by stopped flow CO2 hydration method2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID27788Calculated partition coefficient (clogP) (MlogP)2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.
AID603450Inhibition of human recombinant catalytic domain of carbonic anhydrase 9 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Sulfonamides incorporating boroxazolidone moieties are potent inhibitors of the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII.
AID238211Inhibitory constant against human Carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID328979Inhibition of human full length carbonic anhydrase 5B2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID256967Selectivity ratio for human CA VB over human CA VA2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID272525Inhibition of human cloned CA7 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID258729Inhibitory activity against cloned human CA12006Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
AID1287519Inhibition of Vibrio cholerae beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID299250Inhibition of Helicobacter pylori beta carbonic anhydrase by stopped-flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID311033Inhibition of mouse carbonic anhydrase 132007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID281083Inhibition of human recombinant isozyme CA2 by CO2 hydration method2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID48090Inhibitory activity against human carbonic anhydrase II (hCA II) by using esterase assay method2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.
AID1379902Inhibition of recombinant human full-length carbonic anhydrase 1 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors.
AID1453410Inhibition of Francisella tularensis beta-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID239422Inhibitory potency against catalytic domain of human Carbonic anhydrase IX expressed in Escherichia coli strain BL212005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX.
AID436563Inhibition of human recombinant CA1 by stopped-flow CO2 assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID614107Inhibition of human cloned carbonic anhydrase 9 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1796755CA Inhibition Assay from Article 10.1021/jm021123s: \\Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.\\2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID1796855CA Inhibition Assay from Article 10.1021/jm0494826: \\Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.\\2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID1796582CA Inhibition Assay from Article 10.1021/jm050483n: \\Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.\\2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID1803440CA Inhibition Assay from Article 10.3109/14756366.2013.804072: \\Inhibition of mammalian carbonic anhydrases I-XIV with grayanotoxin III: solution and in silico studies.\\2014Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 29, Issue:4
Inhibition of mammalian carbonic anhydrases I-XIV with grayanotoxin III: solution and in silico studies.
AID1796980CA Inhibition Assay from Article 10.1021/jm060807n: \\Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide anal2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1799734Inhibition Assay from Article 10.1080/14756360802218441: \\Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast ca2009Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 24, Issue:2
Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines.
AID1796595CA Inhibition Assay from Article 10.1021/jm060531j: \\Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.\\2006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID1797528Esterase Assay from Article 10.1021/jm031057+: \\Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.\\2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID1796552CA Inhibition Assay from Article 10.1021/jm0512600: \\Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.\\2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID1798982CA Inhibition Assay from Article 10.1021/jm9003126: \\Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.\\2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID1797276Esterase Assay from Article 10.1021/jm031079w: \\Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.\\2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID1798985CA Inhibition Assay from Article 10.1021/jm9000488: \\Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.\\2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1798769CA Inhibition Assay from Article 10.1021/jm801267c: \\Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.\\2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1798598CA Inhibition Assay from Article 10.1016/j.bmcl.2008.03.051: \\Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.\\2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1799586Inhibition Assay from Article 10.1111/j.1747-0285.2009.00842.x: \\Carbonic anhydrase inhibitors: inhibition of cytosolic carbonic anhydrase isozymes II and VII with simple aromatic sulfonamides and some azo dyes.\\2009Chemical biology & drug design, Aug, Volume: 74, Issue:2
Carbonic anhydrase inhibitors: inhibition of cytosolic carbonic anhydrase isozymes II and VII with simple aromatic sulfonamides and some azo dyes.
AID1799266CA Inhibition Assay from Article 10.1016/j.bmc.2009.05.002: \\Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.\\2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1797360CA Inhibition Assay from Article 10.1021/jm061320h: \\Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.\\2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID1811Experimentally measured binding affinity data derived from PDB2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID1346003Human carbonic anhydrase 4 (4.2.1.1 Carbonate dehydratases)2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1345928Human carbonic anhydrase 1 (4.2.1.1 Carbonate dehydratases)2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1345928Human carbonic anhydrase 1 (4.2.1.1 Carbonate dehydratases)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID1346210Human carbonic anhydrase 12 (4.2.1.1 Carbonate dehydratases)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (293)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990122 (41.64)18.7374
1990's7 (2.39)18.2507
2000's83 (28.33)29.6817
2010's69 (23.55)24.3611
2020's12 (4.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.18 (24.57)
Research Supply Index5.77 (2.92)
Research Growth Index5.26 (4.65)
Search Engine Demand Index69.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (4.25%)5.53%
Reviews10 (3.27%)6.00%
Case Studies10 (3.27%)4.05%
Observational0 (0.00%)0.25%
Other273 (89.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Dichlorphenamide vs. Placebo for Periodic Paralysis [NCT00494507]Phase 371 participants (Actual)Interventional2007-06-30Completed
[NCT00004802]Phase 364 participants Interventional1992-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00494507 (20) [back to overview]HOP Attack Duration
NCT00494507 (20) [back to overview]HOP Attack Rate
NCT00494507 (20) [back to overview]HOP Change From Baseline to Week 9 in Average Manual Muscle Testing (MMT) Score
NCT00494507 (20) [back to overview]HOP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing (MVICT) Scores
NCT00494507 (20) [back to overview]HOP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing Percent of Predicted Normal
NCT00494507 (20) [back to overview]HOP Change From Baseline to Week 9 in Lean Body Mass
NCT00494507 (20) [back to overview]HOP Change From Baseline to Week 9 in SF-36 Mental Health Component Summary Score
NCT00494507 (20) [back to overview]HOP Change From Baseline to Week 9 in SF-36 Physical Component Summary Score
NCT00494507 (20) [back to overview]HOP Endpoint of Acute Worsening
NCT00494507 (20) [back to overview]HOP Severity-weighted Attack Rate
NCT00494507 (20) [back to overview]HYP Attack Duration
NCT00494507 (20) [back to overview]HYP Attack Rate
NCT00494507 (20) [back to overview]HYP Change From Baseline to Week 9 in Average Manual Muscle Testing (MMT) Score
NCT00494507 (20) [back to overview]HYP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing (MVICT) Scores
NCT00494507 (20) [back to overview]HYP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing Percent of Predicted Normal
NCT00494507 (20) [back to overview]HYP Change From Baseline to Week 9 in Lean Body Mass
NCT00494507 (20) [back to overview]HYP Change From Baseline to Week 9 in SF-36 Mental Health Component Summary Score
NCT00494507 (20) [back to overview]HYP Change From Baseline to Week 9 in SF-36 Physical Component Summary Score
NCT00494507 (20) [back to overview]HYP Endpoint of Acute Worsening
NCT00494507 (20) [back to overview]HYP Severity-weighted Attack Rate

HOP Attack Duration

HOP participant total attack duration per week, defined as the sum of attack durations across all distinct attacks over the final 8 weeks (Weeks 2-9) of the double-blind treatment period divided by the number of weeks that the subject was followed. (NCT00494507)
Timeframe: 8 weeks

Interventionhours per week (Median)
HOP Dichlorphenamide2.7
HOP Placebo26.2

[back to top]

HOP Attack Rate

The number of distinct attacks per week over the final 8 weeks (Weeks 2-9) of the double-blind treatment period as self-reported by HOP participants. (NCT00494507)
Timeframe: 8 weeks

Interventionattacks per week (Median)
HOP Dichlorphenamide0.3
HOP Placebo2.4

[back to top]

HOP Change From Baseline to Week 9 in Average Manual Muscle Testing (MMT) Score

"The strength of each of 26 individual muscles was graded using a modified 13-point Medical Research Council scale ranging from 0-5. Recorded grades were converted to numerical values as follows prior to averaging across muscles to form a composite score: 0 = 0; 1 = 1; 2- = 1.67; 2 = 2; 2+ = 2.33; 3- = 2.67; 3 = 3; 3+ = 3.33; 4- = 3.67; 4 = 4; 4+ = 4.33; 5- = 4.67; 5 = 5. A higher score represents a better outcome, i.e. 5 = normal strength.~The following muscles were tested: shoulder abductor (left/right), elbow extensor (left/right), elbow flexor (left/right), wrist extensor (left/right), wrist flexor (left/right), hip flexor (left/right), hip extensor (left/right), hip abductor (left/right), knee extensor (left/right), knee flexor (left/right), ankle dorsiflexor (left/right), ankle plantar flexor (left/right), neck extensor, neck flexor." (NCT00494507)
Timeframe: Baseline and 9 weeks

Interventionunits on a scale (Mean)
HOP Dichlorphenamide0.05
HOP Placebo-0.08

[back to top]

HOP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing (MVICT) Scores

"The strength of each of 10 muscles was measured using quantitative myometry and expressed as the number of standard deviations from normal (Z-score) given the participant's age, gender, and height. The scores were averaged across muscles to form a composite MVICT score: average standardized MVICT score. A positive Z-score indicates a better outcome.~The following muscles were tested: elbow extensor (left/right), elbow flexor (left/right), knee extensor (left/right), knee flexor (left/right), and hand grip (left/right)." (NCT00494507)
Timeframe: Baseline and 9 weeks

InterventionZ-score (Mean)
HOP Dichlorphenamide-0.08
HOP Placebo-0.27

[back to top]

HOP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing Percent of Predicted Normal

"The strength of each of 10 muscles was measured using quantitative myometry and expressed as the percent of predicted normal given the participant's age, gender, and height. The scores were averaged across muscles to form a composite MVICT score: average percent of predicted normal score. A higher number indicates a better outcome.~The following muscles were tested: elbow extensor (left/right), elbow flexor (left/right), knee extensor (left/right), knee flexor (left/right), and hand grip (left/right)." (NCT00494507)
Timeframe: Baseline and 9 weeks

Interventionaverage percent of predicted normal (Mean)
HOP Dichlorphenamide-0.81
HOP Placebo-2.94

[back to top]

HOP Change From Baseline to Week 9 in Lean Body Mass

Lean body mass was measured by dual-energy X-ray absorptiometry (DEXA). (NCT00494507)
Timeframe: Baseline and 9 weeks

Interventionkg (Mean)
HOP Dichlorphenamide-0.78
HOP Placebo0.44

[back to top]

HOP Change From Baseline to Week 9 in SF-36 Mental Health Component Summary Score

The Medical Outcomes Study Short Form (SF-36) questionnaire is a widely used profile measure of generic health-related quality of life. The 36 questions are allocated to eight scales: physical function (PF), physical role (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social function (SF), mental health (MH), and emotional role (RE). The mental health component summary score is calculated from the four scales of VT, SF, MH, and RE. Scores are constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. Higher scores are associated with better quality of life. (NCT00494507)
Timeframe: Baseline and 9 weeks

InterventionT-score (Mean)
HOP Dichlorphenamide-1.10
HOP Placebo-5.65

[back to top]

HOP Change From Baseline to Week 9 in SF-36 Physical Component Summary Score

The Medical Outcomes Study Short Form (SF-36) questionnaire is a widely used profile measure of generic health-related quality of life. The 36 questions are allocated to eight scales: physical function (PF), physical role (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social function (SF), mental health (MH), and emotional role (RE). The physical component summary score is calculated from the four scales of PF, RP, BP, and GH. Scores are constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. Higher scores are associated with better quality of life. (NCT00494507)
Timeframe: Baseline and 9 weeks

InterventionT-score (Mean)
HOP Dichlorphenamide4.83
HOP Placebo-3.75

[back to top]

HOP Endpoint of Acute Worsening

Increase in attack frequency or severity in HOP participants necessitating withdrawal from the initial nine-week double-blind treatment period and moving directly into the open-label phase. (NCT00494507)
Timeframe: 0-9 weeks

Interventionparticipants (Number)
HOP Dichlorphenamide0
HOP Placebo5

[back to top]

HOP Severity-weighted Attack Rate

HOP participant severity-weighted attack rate is defined as the sum of average attack severity across all distinct attacks over the final 8 weeks (Weeks 2-9) of the double-blind treatment period divided by the number of weeks that the subject was followed. Attack severity (scored as 1-10 with increasing severity) is self-reported. (NCT00494507)
Timeframe: 8 weeks

Interventionseverity-weighted attacks per week (Median)
HOP Dichlorphenamide0.6
HOP Placebo5.7

[back to top]

HYP Attack Duration

HYP participant total attack duration per week, defined as the sum of attack durations across all distinct attacks over the final 8 weeks (Weeks 2-9) of the double-blind treatment period divided by the number of weeks that the subject was followed. (NCT00494507)
Timeframe: 8 weeks

Interventionhours per week (Median)
HYP Dichlorphenamide10.5
HYP Placebo39.4

[back to top]

HYP Attack Rate

The number of distinct attacks per week over the final 8 weeks (Weeks 2-9) of the double-blind treatment period as self-reported by HYP participants. (NCT00494507)
Timeframe: 8 weeks

Interventionattacks per week (Median)
HYP Dichlorphenamide0.9
HYP Placebo4.8

[back to top]

HYP Change From Baseline to Week 9 in Average Manual Muscle Testing (MMT) Score

"The strength of each of 26 individual muscles was graded using a modified 13-point Medical Research Council scale ranging from 0-5. Recorded grades were converted to numerical values as follows prior to averaging across muscles to form a composite score: 0 = 0; 1 = 1; 2- = 1.67; 2 = 2; 2+ = 2.33; 3- = 2.67; 3 = 3; 3+ = 3.33; 4- = 3.67; 4 = 4; 4+ = 4.33; 5- = 4.67; 5 = 5. A higher score represents a better outcome, i.e. 5 = normal strength.~The following muscles were tested: shoulder abductor (left/right), elbow extensor (left/right), elbow flexor (left/right), wrist extensor (left/right), wrist flexor (left/right), hip flexor (left/right), hip extensor (left/right), hip abductor (left/right), knee extensor (left/right), knee flexor (left/right), ankle dorsiflexor (left/right), ankle plantar flexor (left/right), neck extensor, neck flexor." (NCT00494507)
Timeframe: Baseline and 9 weeks

Interventionunits on a scale (Mean)
HYP Dichlorphenamide0.13
HYP Placebo0.00

[back to top]

HYP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing (MVICT) Scores

"The strength of each of 10 muscles was measured using quantitative myometry and expressed as the number of standard deviations from normal (Z-score) given the participant's age, gender, and height. The scores were averaged across muscles to form a composite MVICT score: average standardized MVICT score. A positive Z-score indicates a better outcome.~The following muscles were tested: elbow extensor (left/right), elbow flexor (left/right), knee extensor (left/right), knee flexor (left/right), and hand grip (left/right)." (NCT00494507)
Timeframe: Baseline and 9 weeks

InterventionZ-score (Mean)
HYP Dichlorphenamide0.78
HYP Placebo0.55

[back to top]

HYP Change From Baseline to Week 9 in Average Maximum Voluntary Isometric Contraction Testing Percent of Predicted Normal

"The strength of each of 10 muscles was measured using quantitative myometry and expressed as the percent of predicted normal given the participant's age, gender, and height. The scores were averaged across muscles to form a composite MVICT score: average percent of predicted normal score. A higher number indicates a better outcome.~The following muscles were tested: elbow extensor (left/right), elbow flexor (left/right), knee extensor (left/right), knee flexor (left/right), and hand grip (left/right)." (NCT00494507)
Timeframe: Baseline and 9 weeks

Interventionaverage percent of predicted normal (Mean)
HYP Dichlorphenamide10.84
HYP Placebo10.17

[back to top]

HYP Change From Baseline to Week 9 in Lean Body Mass

Lean body mass was measured by dual-energy X-ray absorptiometry (DEXA). (NCT00494507)
Timeframe: Baseline and 9 weeks

Interventionkg (Mean)
HYP Dichlorphenamide-1.31
HYP Placebo-1.52

[back to top]

HYP Change From Baseline to Week 9 in SF-36 Mental Health Component Summary Score

The Medical Outcomes Study Short Form (SF-36) questionnaire is a widely used profile measure of generic health-related quality of life. The 36 questions are allocated to eight scales: physical function (PF), physical role (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social function (SF), mental health (MH), and emotional role (RE). The mental health component summary score is calculated from the four scales of VT, SF, MH, and RE. Scores are constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. Higher scores are associated with better quality of life. (NCT00494507)
Timeframe: Baseline and 9 weeks

InterventionT-score (Mean)
HYP Dichlorphenamide-3.77
HYP Placebo2.65

[back to top]

HYP Change From Baseline to Week 9 in SF-36 Physical Component Summary Score

The Medical Outcomes Study Short Form (SF-36) questionnaire is a widely used profile measure of generic health-related quality of life. The 36 questions are allocated to eight scales: physical function (PF), physical role (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social function (SF), mental health (MH), and emotional role (RE). The physical component summary score is calculated from the four scales of PF, RP,BP, and GH. Scores are constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. Higher scores are associated with better quality of life. (NCT00494507)
Timeframe: Baseline and 9 weeks

InterventionT-score (Mean)
HYP Dichlorphenamide3.16
HYP Placebo-0.11

[back to top]

HYP Endpoint of Acute Worsening

Increase in attack frequency or severity in HYP participants necessitating withdrawal from the initial nine-week double-blind treatment period and moving directly into the open-label phase. (NCT00494507)
Timeframe: 0-9 weeks

Interventionparticipants (Number)
HYP Dichlorphenamide0
HYP Placebo2

[back to top]

HYP Severity-weighted Attack Rate

HYP participant severity-weighted attack rate is defined as the sum of average attack severity across all distinct attacks over the final 8 weeks (Weeks 2-9) of the double-blind treatment period divided by the number of weeks that the subject was followed. Attack severity (scored as 1-10 with increasing severity) is self-reported. (NCT00494507)
Timeframe: 8 weeks

Interventionseverity-weighted attacks per week (Median)
HYP Dichlorphenamide1.0
HYP Placebo5.8

[back to top]